Zobrazeno 31 - 40
of 1 548
pro vyhledávání: ''
Autor:
Alexander J. Lazar, Roman Groisberg, Vivek Subbiah, Robert E. Brown, Daniella E Portal, Aung Naing, Neeta Somaiah, Maria Alejandra Zarzour, Cynthia E. Herzog, Jason Roszik, Anthony P. Conley, David S. Hong, Shreyaskumar Patel
Publikováno v:
Mol Cancer Ther
Overexpression of transcription factor 3 in alveolar soft part sarcoma(ASPS) results in upregulation of cell proliferation pathways. No standard treatment algorithm exists for ASPS; multikinase inhibitors[tyrosine kinase inhibitor (TKI)] and immune c
Autor:
Umang Shah, Matthew C. Coffey, Himanshu Kharkwal, Sanjay Goel, Allyson J. Ocean, Sengottuvel Viswanathan, Imran Chaudhary, M. H. Ghalib, Ruwan Parakrama, Radhashree Maitra
Publikováno v:
Molecular Cancer Therapeutics. 19:1148-1156
KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS-mutated cells, and is syn
Autor:
Serguei Kozlov, Ming Yi, Suman Mukhopadhyay, William E. Burgan, Dwight V. Nissley, Debanjan Goswami, Pavan P. Adiseshaiah, Frank McCormick, Theresa Guerin
Publikováno v:
Cancer research, vol 80, iss 8
Pancreatic cancer is a disease with limited therapeutic options. Resistance to chemotherapies poses a significant clinical challenge for patients with pancreatic cancer and contributes to a high rate of recurrence. Oncogenic KRAS, a critical driver o
Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma
Publikováno v:
Clin Cancer Res
Purpose: To determine the expression of glucocorticoid receptor (GR) and androgen receptor (AR) in salivary duct carcinoma (SDC) and to analyze the role of these proteins in the development and management of this disease entity. Experimental Design:
Autor:
Kei-ichiro Arimoto, Leo J.Y. Kim, Balázs Győrffy, Klaus-Peter Knobeloch, Dong-Er Zhang, Hua Cheng, Christoph Burkart, Xiang-Dong Fu, Jeremy N. Rich, Hu Cang, Jun-Bao Fan, Yu Zhou, Hui-Zhong Xu, Ming Yan, Sayuri Miyauchi, Dan Liu
Publikováno v:
Cancer Discov
Type I interferons (IFN), which activate many IFN-stimulated genes (ISG), are known to regulate tumorigenesis. However, little is known regarding how various ISGs coordinate with one another in developing antitumor effects. Here, we report that the I
Autor:
Weiwei Jin, Lianpeng Chang, Song Ye, Jiahong Jiang, Huaixiang Zhou, Yaping Xu, Liu Yang, Xiaoge Hu, Chao Ni
Publikováno v:
Molecular Cancer Therapeutics. 19:956-965
With the increase of treatment course, resistance to EGFR blockade is inevitable in patients with metastatic colorectal cancer (mCRC). KRAS mutations have been considered to be primary drivers of this resistance; however, the potential function of ot
Autor:
Mariaelena Pierobon, Leslie S L Kim, Lance A. Liotta, Maren K Levin, Emanuel F. Petricoin, Elisa Baldelli, Joyce O'Shaughnessy
Publikováno v:
Cancer Research. 80:P4-10
Background: ER- HER2+ BC is comprised of a heterogeneous mix of intrinsic BC subtypes which have differential responsiveness to preop HER2-directed therapies combined with chemotherapy. Patients (pts) with ER- HER2+ BC whose disease progressed while
Autor:
Sri HariKrishna Vellanki, Mattia Cremona, Saraswati Sukumar, Alexander Casucci, Ciara Flynn, Yvonne E. Smith, Lance Hudson, Ann M. Hopkins, Kieran Brennan, Guannan Wang
Publikováno v:
Cancer Research. 80:P3-06
Background/Aim: Increased expression of the cell-cell adhesion molecule Junctional Adhesion Molecule-A (JAM-A) has been associated with poor prognosis and HER2 expression in patients with invasive ductal breast cancera,b. However, little is known abo
Autor:
Sachin K. Khiste, Mohammad Burhan Uddin, Ronald A. Hill, Sami Nazzal, Zhijun Liu, Xin Gu, Salman B. Hosain, Kartik R. Roy, Yong-Yu Liu
Publikováno v:
Mol Cancer Ther
Ceramide (Cer) is an active cellular sphingolipid that can induce apoptosis or proliferation-arrest of cancer cells. Nanoparticle-based delivery offers an effective approach for overcoming bioavailability and biopharmaceutics issues attributable to t
Autor:
Alex Pearson, Maria Teresa Herrera-Abreu, Alistair Ring, Paula Proszek, E Schuster, Ashutosh Nerurkar, David Gonzalez de Castro, Lina Yuan, Brian A Walker, Ben O'Leary, Javier Pascual, Marina Parton, Mike Hubank, Alicia Okines, Isaac Garcia-Murillas, Stephen R. D. Johnston, Elena Lopez-Knowles, Peter Osin, Mitch Dowsett, Rosalind J. Cutts, Monee K Shamsher, Hannah Bye, Sabri Jamal, Belinda Kingston, Charlotte Fribbens, Nicholas C. Turner
Publikováno v:
Clinical Cancer Research. 26:608-622
Purpose: Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential to acquire mutations with